Review Papers Claim by Claim

 Quick Explanation Copied

 Long Explanation

What the paper actually demonstrates

Four steroid dimers (estradiol, 3-O-methyl-estradiol, testosterone, pregnenolone) were synthesized via CuAAC click chemistry using a 2,6-bis(azidomethyl)pyridine linker (78–87% yields, ≥95% HPLC purity) Synthesis and characterization of dimers 1-4. Only the estradiol dimer (1) potently inhibited purified porcine-brain tubulin polymerization (IC50 3.6 µM; nocodazole 1.5 µM; clearly stronger than 2-methoxyestradiol). At 2.5 µM it completely and reversibly depolymerized interphase U2OS microtubules; at 50 nM it reduced microtubule dynamicity ~25% (nocodazole ~37%) measured via EB1-GFP plusTipTracker tracking (n = 31–37 cells, 3 experiments, p < 0.0001) Tubulin assembly and microtubule dynamics data. Critically, dimerization abolished ERα/AR transactivation (4–5 orders of magnitude weaker estrogenicity), ruling out a genomic steroid-receptor mechanism — a well-designed negative control series (ethynylated monomers inactive at 10 µM) strengthens the causality of this claim Steroid receptor reporter assays.

The resistance profile is mechanistically informative: the MVP-overexpressing CEM-DNR line is ~193× more resistant than parental CCRF-CEM, while P-gp-only lines (K562-TAX, HeLa) remain sensitive — the authors' inference that MVP, not P-gp, transports the dimer out is plausible but unproven MDR resistance profiling.

Critical assessment — known vs inferred vs uncertain

Known (reported): all quantitative values above, plus G2/M arrest with elevated pH3Ser10 and reduced BrdU/BrU incorporation in CCRF-CEM. Inferred (authors): binding to the colchicine site — supported only by a single 100 ns GROMACS MD run starting from a manually docked pose; no co-crystal, no competition assay with colchicine, no tubulin-mutant validation. Uncertain: whether dimer 1 is truly selective for the colchicine site vs nonspecific hydrophobic aggregation (PAINS filtering was done, but PAINS filters miss colloidal aggregators, the most common false-positive mechanism for large hydrophobic dimers at low µM). Notably, MD was run only on the stable pose — no negative control simulation of the inactive dimers, a missed opportunity.

Blind spots: porcine tubulin may differ from human β-tubulin isotypes relevant to colchicine-site affinity; therapeutic index on MRC-5/BJ fibroblasts was low (0.01–22.98), which the authors mention but underweight; no in vivo efficacy or pharmacokinetics; the claim that 2-ME "lacks" dynamicity effects conflicts with some literature but is tested here under only one condition (50 nM, 3 h). What would falsify the mechanism: a colchicine-competition assay or β-tubulin colchicine-site mutant retaining dimer activity; failure of structurally matched inactive dimers to behave as controls was already partially addressed by the monomer series.

Bottom line: a well-executed, internally consistent communication establishing a new steroidal chemotype of tubulin destabilizer. The biochemical and cellular evidence is solid; the structural mechanism is hypothesis-generating only, and clinical relevance is distant.

Author reviews: M. JurášekM. ČernohorskáJ. ŘehulkaV. SpiwokT. SulimenkoE. DráberováM. DarmostukS. GurskáI. FrydrychR. BuriánováT. RumlM. HajdúchP. BartůněkP. DráberP. DžubákP. B. DrašarD. Sedlák

 BGPT Paper Review

Study Novelty

First report of an estradiol dimer as a potent tubulin polymerization inhibitor; prior steroidal antimitotics (2-ME, estramustine) are monomeric, making this a genuinely new chemotype, though dimeric steroid cytotoxins (cephalostatins) exist naturally.

Scientific Quality

Strong multi-assay consistency (biochemistry, cells, dynamics, resistance panel) with proper inactive monomer controls; weakened by docking-only structural claims without colchicine-competition or co-crystal validation, single MD run, porcine tubulin, and low therapeutic index on fibroblasts.

Study Generality

Establishes dimerization as a route to non-genomic cytoskeletal steroid activity relevant to anticancer chemistry, but conclusions are specific to one compound in one linker scaffold with no in vivo or clinical generalization.

Study Usefulness

Provides a validated new antimitotic steroidal scaffold, a clear SAR (only estradiol dimer active), and an MVP-resistance handle useful for medicinal chemistry optimization.

Study Reproducibility

Detailed synthetic protocols, NMR/HRMS characterization, standard MTT, flow cytometry, and plusTipTracker parameters are reported; no deposited data/code and MD details partly in supporting information.

Explanatory Depth

Mechanistic chain from polymerization inhibition to G2/M arrest is well-supported; the atomic-level binding explanation rests on unvalidated docking/MD, limiting depth.